NIPPV vs.nCPAP During LISA Procedure (NIPAL)
Respiratory Distress Syndrome, Newborn
About this trial
This is an interventional treatment trial for Respiratory Distress Syndrome, Newborn focused on measuring Surfactant, LISA procedure, Preterm infant
Eligibility Criteria
Inclusion Criteria: -Infants with gestational age between 25+0 and 31+6 gestational weeks, -RDS which does not require MV -Treatment with NCPAP and FiO2 >0.30 within the first 6 hours of life, -First dose of caffeine administered Exclusion Criteria: -absence of informed consent, -major congenital malformations, -hydrops fetalis, -chromosomal diseases, -previous treatment with surfactant, -cardiorespiratory instability requiring treatment with vasoactive drugs, -pneumothorax, -death within 72 hours of life.
Sites / Locations
- Careggi University Hospital, Division of Neonatology
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
LISA with NCPAP
LISA with NIPPV
In this group, infants will receive NCPAP during LISA procedure.
In this group, infants will receive NIPPV during LISA procedure.